Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1707 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
NCT05681819Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Feb 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing SHR-1707 with SHR-1707 placebo (2 arms). Primary endpoints: Number of patients with adverse events at 26 weeks, Number of patients with clinically significant change from baseline in vital signs values at 26 weeks and 4 more. Started Feb 2023; status: completed.
02
Drugs
SHR-1707
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05681819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681819.